Organogenesis (NASDAQ:ORGO) Trading Down 2.1% - Here's Why

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report)'s share price fell 2.1% on Friday . The company traded as low as $5.10 and last traded at $5.14. 220,836 shares were traded during trading, a decline of 79% from the average session volume of 1,071,226 shares. The stock had previously closed at $5.25.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their target price on shares of Organogenesis from $4.00 to $6.00 and gave the stock an "equal weight" rating in a report on Wednesday, March 5th.

Organogenesis Trading Up 0.4 %

The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The firm has a market cap of $632.87 million, a PE ratio of -83.17 and a beta of 1.66. The stock's 50 day simple moving average is $3.93 and its 200 day simple moving average is $3.46.

Insiders Place Their Bets

In other Organogenesis news, Director Michael Joseph Driscoll sold 25,000 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the completion of the transaction, the director now owns 166,879 shares of the company's stock, valued at $851,082.90. The trade was a 13.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 36.90% of the company's stock.

Remove Ads

Institutional Investors Weigh In On Organogenesis

A number of institutional investors have recently made changes to their positions in ORGO. Metis Global Partners LLC purchased a new stake in shares of Organogenesis in the 3rd quarter valued at $84,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Organogenesis by 5.6% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 471,240 shares of the company's stock valued at $1,348,000 after buying an additional 24,878 shares during the last quarter. Intech Investment Management LLC bought a new stake in Organogenesis during the 3rd quarter valued at $43,000. Charles Schwab Investment Management Inc. raised its holdings in Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company's stock valued at $2,713,000 after buying an additional 23,675 shares during the last quarter. Finally, FMR LLC raised its holdings in Organogenesis by 34.2% during the 3rd quarter. FMR LLC now owns 173,595 shares of the company's stock valued at $496,000 after buying an additional 44,199 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company's stock.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.